Not available
Quote | Moleculin Biotech Inc. (NASDAQ:MBRX)
Last: | $4.65 |
---|---|
Change Percent: | -1.47% |
Open: | $4.59 |
Close: | $4.65 |
High: | $4.66 |
Low: | $4.4001 |
Volume: | 10,562 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Moleculin Biotech Inc. (NASDAQ:MBRX)
2024-04-18 09:13:59 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML Seeking Alpha’s Quant Rating on Moleculin Biotech H...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine a...
Message Board Posts | Moleculin Biotech Inc. (NASDAQ:MBRX)
Subject | By | Source | When |
---|---|---|---|
We all have witnessed this stock with good | TheSprinx | investorshub | 04/20/2023 3:18:19 PM |
$MBRX THIS IS GOOD >>---> As of December | TheFinalCD | investorshub | 04/19/2023 11:50:12 AM |
Recent Highlights | TheFinalCD | investorshub | 04/19/2023 11:48:28 AM |
.75 walk down on air shares this morning | TheFinalCD | investorshub | 04/19/2023 9:15:37 AM |
https://www.prnewswire.com/news-releases/moleculin-announces-presentation-of-pos | Dennisb68 | investorshub | 04/18/2023 10:47:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine a...
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties PR Newswire Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against establi...
2024-03-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...